PER® Miami Breast Cancer Conference | Conference

Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBC

March 8th 2024

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer

March 8th 2024

Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

March 7th 2024

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant Therapy

March 7th 2024

Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

March 8th 2023

Susan M. Domchek, MD, highlights key points related to her presentation on germline testing and breast cancer treatment.

Metronomic Chemotherapy Represents Late Treatment Option for Some Patients With Metastatic Breast Cancer

March 6th 2023

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

Dr. Carey on the Response-Guided Therapy in HER2+ Breast Cancer

March 5th 2023

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

Dr. Borgen on the Importance of Addressing Opioid Use in Breast Cancer Care

March 5th 2023

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.

Real-World Outcomes With Sacituzumab Govitecan Match ASCENT in Single-Center Study

March 5th 2023

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.

Miami Breast Keynotes Highlight the Call to Action for Advocacy Efforts in Breast Cancer

March 4th 2023

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

Treatment in HR+ Early Breast Cancer May be Best Guided by Risk of Recurrence

March 4th 2023

After settling the debate of which patients with early-stage, hormone receptor–positive breast cancer require chemotherapy in addition to endocrine therapy, investigators have set their sights on determining whether ovarian function suppression can deliver the same effects of chemotherapy and when to recommend abemaciclib and olaparib.

SERMS, SERDS, and PROTEC Are Poised to Shake Up Treatments for ER+ Breast Cancer

March 4th 2023

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

Progress in Treating Brain Metastases in Breast Cancer Puts Multidisciplinary Approaches Into Focus

March 4th 2023

Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system metastases.

Dr. Chagpar on Financial Toxicity and Disparities in Breast Cancer

March 4th 2023

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the unmet needs regarding financial toxicities for patients with breast cancer.

Artificial Intelligence, MRI, and Interdisciplinary Collaboration Topics Draw Radiologists, Surgeons to Miami

March 4th 2023

The growth of artificial intelligence allows physicians to see tumors in unprecedented ways.

Dr. Chmura on the Management of Oligometastatic Breast Cancer

March 3rd 2023

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Dr. Kalinsky on the Evolving Treatment Landscape and Sequencing ADCs in TNBC

March 3rd 2023

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

I-SPY 2 Framework Could Represent the Future of Drug Development in Breast Cancer

March 3rd 2023

By moving away from adjuvant- to neoadjuvant-based protocols, such as I-SPY, investigators may be better able to develop effective treatments for patients in less time by refining the understanding of who will benefit from therapy, enabling strategies with multiple pathway targets, and testing approaches earlier in the disease course.

ADC Developments in HER2– Breast Cancer Treatment Shake Up Paradigm

March 3rd 2023

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.

Dr. Hunt on Axillary Reverse Mapping in Breast Cancer

March 3rd 2023

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.